Promoting IMMUNE TOLERANCE, ameliorating disease

Anokion SA

Incorporated

15.03.2010

Headquarters

Ecublens

Support

Many therapeutic protein drugs are perceived by the body as foreign entities and are hence targeted for attack and clearance by the immune system, thus rendering treatment ineffective and potentially dangerous. Anokions platform immune tolerance technology harnesses the power of natural immune regulation by engineering therapeutic proteins to be perceived as self entities, thereby offering a means to reduce immunogenicity of existing therapeutics and further enable clinical translation of proteins previously thought to be too immunogenic for repeated use.

Patients suffering from autoimmune diseases harbor immune cells that erroneously recognize naturally occurring self-proteins as foreign, causing tissue destruction and inflammation. The current therapeutic modality for treating such